Saturday - September 13, 2025
MD Anderson and Phoenix SENOLYTIX Announce Strategic Cross-licensing Agreement to Enhance Inducible Switch Technologies for Cell and Gene Therapies
September 05, 2025
HOUSTON, Texas, Sept. 5 -- The University of Texas MD Anderson Cancer Center issued the following news release:

* * *

MD Anderson and Phoenix SENOLYTIX announce strategic cross-licensing agreement to enhance inducible switch technologies for cell and gene therapies

* Agreement focuses on rimiducid, an agent used to activate certain safety switch technologies in cell therapies

* Phoenix receives a supply of rimiducid and support to seek regulato . . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Name:
What's your
Affiliation		 Government Newspaper / Media Business
Public Policy Individual / Student Educators
Email:
Phone:
Organization, if any:
State/Country you are in:
Additonal questions
or comments:

Click here for more information about our products

Click here for more information about our products